Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F527 in Relapsed or Refractory Lymphoma
NCT05293028Phase 1Unknown
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- May 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of F527 in lymphoma, sponsored by Shandong New Time Pharmaceutical. Primary endpoints: Dose-Limiting Toxicities up to 21 days, Maximum Tolerated Dose up to 21 days and 1 more. Status: unknown.
02
Drugs
F527
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05293028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293028.